...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell cycle >Chromosome Iq gain is not associated with a poor outcome in childhood medulloblastoma Requirements for the validation of potential prognostic biomarkers
【24h】

Chromosome Iq gain is not associated with a poor outcome in childhood medulloblastoma Requirements for the validation of potential prognostic biomarkers

机译：染色体智商增加与儿童成年髓母细胞瘤的不良预后无关验证潜在预后生物标志物的要求

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Despite improved outcomes over the last three decades, therapies for childhood medulloblastoma, the most common malignant brain tumor of childhood, are still associated with significant rates of relapse and adverse late-effects. Patients are currently stratified into disease-risk groups on the basis of clinical factors, but these fail to account for significant outcome differences among patients within groups. Improved disease-risk assessment will be central to future patient management, with the dual goals of delivering intensive therapies to high-risk cases while reducing late-effects in favorable-risk cases, and molecular genetic biomarkers offer significant potential in this regard.1 Lo et al. recently reported the potential value of a single-copy gain of the q-arm of chromosome 1 as a highly significant predictor of poor overall survival in medulloblastoma (p < 0.0001, log-rank test), in a study based on an array-comparative genomic hybridisation analysis of chromosomal imbalances in a cohort of 49 cases with a relatively short median follow-up time of 39 months
机译：尽管在过去的三十年中治疗效果有所改善，但治疗儿童髓样母细胞瘤（儿童期最常见的恶性脑瘤）的治疗方法仍具有较高的复发率和不良的后遗症。目前，根据临床因素将患者分为疾病风险组，但是这些不能解释各组患者之间显着的预后差异。改进的疾病风险评估将是未来患者管理的中心，其双重目标是为高风险病例提供强化治疗，同时减少有利风险病例的后遗症，而分子遗传标志物在这方面具有巨大潜力。1Lo等。最近在一项基于阵列比较的研究中报道，染色体1的q臂单拷贝获得的潜在价值可作为髓母细胞瘤总体生存不良的高度重要的预测指标（p <0.0001，对数秩检验）基因组杂交分析49例患者的染色体失衡，中位随访时间较短，为39个月

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号